Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Bioxtreme Announces Strategic Investment Led by Serra Holding and Introduces Plaxtreme to Accelerate Neurorehabilitation Innovation
Leadership Expansion Across the U.S. and Europe Supports Global Growth of Next-Generation Neurorehabilitation Robotics
Bioxtreme, an innovator in neurorehabilitation technologies leveraging its proprietary error augmentation approach to accelerate motor recovery, today announced a new strategic investment led by Serra Holding, a family office focused on hands-on investment and operational support across the healthcare sector, including hospitals, mental health institutions, and medtech companies. This investment brings the company’s total funding to $15 million to date, accelerating Bioxtreme’s global expansion, strengthening operations in the United States and Europe, and supporting the launch of Plaxtreme, the company’s advanced robotic rehabilitation device engineered to drive neuroplasticity and accelerate motor skill recovery in individuals with neurological conditions.
Plaxtreme is designed to address the restoration of functional hand movement. Combining precision robotics, immersive virtual environments, and Bioxtreme’s proprietary error augmentation technology, Plaxtreme restores grasp and release while accelerating recovery and improving functional outcomes for users. Key capabilities include:
- Patented Error Augmentation Technology – Amplifies movement errors to trigger the brain’s natural adaptive responses, accelerating motor learning and improving movement accuracy
- Personalized Adaptive, AI-Based Learning– AI analyzes movement performance in real time, adjusting subtle force demands and therapy parameters; continuously adapts to support progressive learning
- Supination and Pronation Training- Supports natural forearm rotation for functional movement, improves coordination for daily tasks; functional, ADL-based activities in an interactive, 3D environment; gamified tasks drive engagement and high repetition practice
- Adaptive Feedback Driven Rehabilitation – Real-time, visual feedback supports continuous progress; automatically adapts difficulty to the patient’s ability
- Designed for Smooth, OT Workflows – Quick setup with no complex calibration, and seamless left/right and transition; convenient hand positioning for efficient clinical use
Bioxtreme’s portfolio also includes Dextreme, an advanced robotic rehabilitation system for upper-limb recovery that also applies adaptive error augmentation forces to accelerate motor learning and restore functional independence…
Full release here, originally announced April 21st, 2026.
Amperos Health Secures $16M Investment as it Launches Industry’s First AI-Native Denial Management and Revenue Recovery Platform
Helping Providers Resolve Denials Five Times Faster and Cut Denial Rates by 70%
Amperos Health, the first insurance revenue recovery partner capable of working denials end-to-end entirely with AI, announced today that it has closed a $16 million Series A funding round, led by Bessemer Venture Partners, with participation from Uncork Capital and Neo.
The raise comes as Amperos launches the industry’s first AI-native denial management and revenue recovery solution for healthcare providers. Amperos’ agentic capabilities provide end-to-end denial and collection automation, while a team of subject matter experts provides judgment and expertise for complex and difficult-to-recover claims. Amperos then delivers detailed insights into how providers can optimize their billing and collections processes to prevent future denials. To date, Amperos has served over 3,000 clinical locations across all 50 states, driving nearly $700 million of revenue recovered per year across over 500,000 claims.
“Complexity in healthcare revenue cycle management (RCM) should not be the norm, and that’s why our mission at Amperos is to streamline the denial and collections process so providers can focus on what matters most – operating their practices and serving their patients,” said Michal Miernowski, Co-Founder and CEO at Amperos Health. “I’m thrilled to announce our most recent funding round, which will be critical as Amperos accelerates its growth to serve more providers, expands its analytics capabilities, and launches new agentic capabilities in other RCM workflows.”
Denials are rising in healthcare today, with 12% of claims denied in 2024, representing a $262 billion loss in revenue to providers. Providers then spend more than $26 billion annually in recovering these denied claims, of which 70% end up getting paid. And yet, 63% of RCM teams are understaffed, while healthcare administration teams face a 32% annual turnover rate.
These statistics exemplify why Amperos has built a new product that can fill gaps in the RCM workforce while recovering more value in denied revenue. The product manages the full denial management process, from following up through insurance portals and calls to submitting corrected claims, medical records, and appeals.
“Denials are one of healthcare’s fastest-growing pain points: a growing portion of claims denied, hundreds of billions in lost revenue, and RCM teams that are chronically understaffed. It’s a broken process ripe for AI transformation,” said Sofia Guerra, Partner at Bessemer Venture Partners…
Full release here, originally announced April 22nd, 2026.
No comments:
Post a Comment